Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia - Conference Call
Jun 29, 2021 at 8:30 AM EDT
Supporting Materials
Cerevel is now part of AbbVie
Together we will deliver science that takes us closer to meaningful change for people with neurological and psychiatric disorders.